 Spectrum --
May 2008
 Introduction:
Asian economic might is growing, and the Asian
pharmaceutical markets and industry are growing along with it. Western
pharmaceutical companies have become very interested in entering Asian markets
and taking advantage of the opportunities they offer. Cost cutting alone,
however, should not be the sole reason for multinational companies (MNCs) to
outsource activities to Southeast Asia. Companies must make the effort to
understand the local culture and business environment in each country they want
to enter if they are to avoid unrealistic expectations and disappointments. The
negative long-term effects could overshadow the benefits of short-term gains.
Although Asian markets may prove challenging, they also offer significant
opportunities for companies that focus their needs and then execute
well-conceived strategies in specific countries.
Get the Answers You Need to Shape Your Strategy:
 PricewaterhouseCoopers forecasts that by 2020, the
pharmaceutical markets of E7 countries will expand to capture 14% of an $800
billion global market. What are the most important factors and recent
activities that are affecting the rise and fall of pharmaceutical importance in
Asia? What opportunities does this growth present for Western pharmaceutical
companies, and how might this significant growth pose a threat to the same
companies?
There is no "one-size-fits-all" approach to doing business in
an Asian country. Each company must address its own needs and goals and develop
its own strategies. What are the most important short- and long-term
implications for branded and generics pharmaceutical companies that want to operate
in Asian markets?
The quality of Chinese-manufactured drugs and the thoroughness
of FDA inspections was brought sharply into focus in early 2008 when as many as
81 deaths and hundreds of allergic reactions occurred in people taking Baxter
Healthcare’s heparin. What are some of the drawbacks of doing business in
Southeast Asia, and what is being done to improve the situation?
Local Asian companies are moving up the value chain of
pharmaceutical drug development. What opportunities are available to them
and what types of business alliances are they forming? In the long term, what
does the future hold for these companies?
Scope:
Surging growth in Asian economies: a look at the
expanding pharmaceutical markets of Asia and the implications that this growth
has for global pharmaceutical players.
Asian pharmaceutical market dynamics: outsourcing
activities, emerging markets, and intellectual property landscapes.
China: market characteristics, growth in API
manufacture, and R&D outsourcing activities.
India: market characteristics, intellectual property
issues, growth in API manufacture, R&D outsourcing activities, and recent
dealmaking activities.
Japan: market characteristics and recent areas of
growth.
Coverage of other growing Asian pharmaceutical markets:
South Korea, Thailand, Singapore, and others.
Outlook: short- and long-term implications of Asian
markets on global pharmaceutical industries.
|
